Zhang Xiaoling, Dong Zhiwei, Zhang Cheng, Ung Choong Yong, He Shuning, Tao Ting, Oliveira Andre M, Meves Alexander, Ji Baoan, Look A Thomas, Li Hu, Neel Benjamin G, Zhu Shizhen
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.
Department of Molecular Pharmacology and Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.
Cell Rep. 2017 Mar 21;18(12):2932-2942. doi: 10.1016/j.celrep.2017.02.065.
Growing evidence suggests a major role for Src-homology-2-domain-containing phosphatase 2 (SHP2/PTPN11) in MYCN-driven high-risk neuroblastoma, although biologic confirmation and a plausible mechanism for this contribution are lacking. Using a zebrafish model of MYCN-overexpressing neuroblastoma, we demonstrate that mutant ptpn11 expression in the adrenal gland analog of MYCN transgenic fish promotes the proliferation of hyperplastic neuroblasts, accelerates neuroblastomagenesis, and increases tumor penetrance. We identify a similar mechanism in tumors with wild-type ptpn11 and dysregulated Gab2, which encodes a Shp2 activator that is overexpressed in human neuroblastomas. In MYCN transgenic fish, Gab2 overexpression activated the Shp2-Ras-Erk pathway, enhanced neuroblastoma induction, and increased tumor penetrance. We conclude that MYCN cooperates with either GAB2-activated or mutant SHP2 in human neuroblastomagenesis. Our findings further suggest that combined inhibition of MYCN and the SHP2-RAS-ERK pathway could provide effective targeted therapy for high-risk neuroblastoma patients with MYCN amplification and aberrant SHP2 activation.
越来越多的证据表明,含Src同源2结构域的磷酸酶2(SHP2/PTPN11)在MYCN驱动的高危神经母细胞瘤中起主要作用,尽管缺乏生物学证实以及对此作用的合理机制。利用MYCN过表达神经母细胞瘤的斑马鱼模型,我们证明在MYCN转基因鱼的肾上腺类似物中突变型ptpn11的表达促进了增生性神经母细胞的增殖,加速了神经母细胞瘤的发生,并增加了肿瘤发生率。我们在具有野生型ptpn11和失调的Gab2的肿瘤中发现了类似机制,Gab2编码一种在人类神经母细胞瘤中过表达的Shp2激活剂。在MYCN转基因鱼中,Gab2过表达激活了Shp2-Ras-Erk途径,增强了神经母细胞瘤的诱导,并增加了肿瘤发生率。我们得出结论,在人类神经母细胞瘤发生过程中,MYCN与GAB2激活的或突变的SHP2协同作用。我们的研究结果进一步表明,联合抑制MYCN和SHP2-RAS-ERK途径可为具有MYCN扩增和异常SHP2激活的高危神经母细胞瘤患者提供有效的靶向治疗。